Cingulate Inc. (CING) 股票分析

公司概述

Cingulate Inc. operates as a biopharmaceutical entity dedicated to developing pharmaceutical products through its proprietary drug delivery platform technology, specifically targeting the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety within the United States market. The company functions within the healthcare sector and is classified specifically under the biotechnology industry, a classification that implies a focus on high-risk, high-reward research and development activities rather than established commercial manufacturing. As of the latest available data, the company holds a market capitalization of $69.31 million and employs a workforce of 14 individuals. These valuation and staffing figures indicate that Cingulate Inc. is a micro-cap enterprise with a relatively small operational footprint, suggesting that its financial resources are currently concentrated primarily in early-stage product development rather than large-scale commercialization or extensive sales infrastructure.

财务健康

The company reported a net income of $-22,449,912 for the trailing twelve months, while EBITDA stood at $-19,397,214, revealing a significant gap between operating earnings and bottom-line profit due to non-operating expenses or other comprehensive income/loss items affecting the net income figure. Although specific revenue figures for the trailing twelve months are not disclosed in the available data, the substantial negative net income relative to the reported metrics indicates a cost structure where expenses significantly exceed any reported income generation. The free cash flow is recorded at $-10,425,198, which signifies a continued burn rate characteristic of biotechnology firms in development phases, limiting immediate financial flexibility for expansion without additional capital raising. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, indicating that the company has not yet achieved profitability or that revenue recognition methods result in zero margins at this stage of development. On the balance sheet, the company holds $10.95 million in cash against $8.79 million in debt, resulting in a debt-to-equity ratio of 350.21, which suggests a highly leveraged position relative to equity, though the absolute debt level is manageable given the cash reserves. The current ratio stands at 1.16, indicating that the company possesses sufficient current assets to cover its current liabilities, thereby maintaining a baseline level of short-term liquidity despite the overall negative financial performance. Furthermore, the return on equity is -450.6% and the return on assets is -83.2%, metrics that reveal management is currently generating negative returns on both shareholder capital and total assets, reflecting the typical challenges faced by pre-revenue biotech companies.

估值评估

The trailing twelve-month P/E ratio is not applicable (N/A) due to the lack of positive earnings, while the forward P/E is calculated at -4.10, a metric that is distorted by the negative earnings trajectory and implies that traditional earnings-based valuation models are not currently applicable to this asset. The price-to-book ratio is 17.23, which indicates a significant market premium over the company's book value, suggesting that investors are pricing the firm based on potential future value of its drug delivery platform rather than its current tangible assets. Alternative valuation metrics such as the price-to-sales ratio (N/A) and EV/EBITDA of -3.46 further highlight the limitations of standard valuation multiples for a company with no revenue and negative earnings, necessitating a reliance on pipeline potential for valuation justification. Regarding price action, the stock has traded between a 52-week low of $3.20 and a 52-week high of $11.89, with the current market price sitting at a level that requires calculation relative to this specific historical range to determine the percentage deviation from the recent highs or lows. The beta value is -0.77, a highly unusual and negative coefficient that indicates the stock's price volatility moves inversely to the broader market, meaning that when the market rises, this stock tends to fall and vice versa, creating a unique risk profile distinct from standard equity assets.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue, yet the negative net income confirms that the company is not currently generating earnings growth and is instead focused on capitalizing on its development pipeline. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute cash to shareholders but instead retains its limited cash flow to fund operations and research. Given the negative earnings and lack of dividends, the company reinvests all available resources into its drug delivery platform technology rather than providing income to investors, a strategy typical for biotechnology firms in the research phase. Overall, the growth and income profile of Cingulate Inc. is characterized by an absence of current revenue generation, zero dividend income, and a reliance on external capital or internal cash reserves to sustain development efforts until potential product approvals occur.